Review Article
Danshen Formulae for Cancer: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
Table 5
Risk of bias assessments for included studies.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A, random sequence generation (selection bias); B, allocation concealment (selection bias). C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment(detection bias). E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. +, low risk of bias;–, high risk of bias; ?, unclear risk of bias. |